A representation of the country’s rapidly developing capability can be seen in the example of WuXi Biologics ... Only last month, the US company Merck agreed to pay a potential $1.4 billion ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap value stocks. Why is this Portfolio Manager Cautiously Optimistic? The market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WuXi STA expects to hire about 500 people in the coming years to support Phase 1 of the manufacturing campus. A Chinese pharmaceutical company is moving forward with plans to build a massive $510 ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.